About Verenium (NASDAQ:VRNM)
Verenium Corporation (Verenium) is an industrial biotechnology company. The Company develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2012, it marketed commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into four product lines: animal health and nutrition, grain processing, oilfield services and other industrial processes. As of December 31, 2012, it markets nine commercial enzyme products. In October 2013, BASF SE acquired 71% stake in the Company.
Industry, Sector and Symbol
Industry Commodity Chemicals
Trailing P/E Ratio-2.55769230769231
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Verenium (NASDAQ:VRNM) Frequently Asked Questions
What is Verenium's stock symbol?
Verenium trades on the NASDAQ under the ticker symbol "VRNM."
Who are some of Verenium's key competitors?
Some companies that are related to Verenium include Northern Technologies International (NTIC), TransAtlantic Petroleum (TNP), CENTRIC HEALTH (CHH), Oryx Petroleum (OXC), Pine Cliff Energy (PNE), Essential Energy Services (ESN), Strad Energy Services (SDY), Atlas Iron (AGODY), Aura Minerals (ORA), Medusa Mining (MML), Kingsgate Consolidated (KCN), Newalta (NAL), Geodrill (GEO), RMP Energy (RMP), Titanium (TIC), Bellatrix Exploration (BXE), Tigers Realm Coal (TIG) and Vista Gold (VGZ).
Who are Verenium's key executives?
Verenium's management team includes the folowing people:
- James H. Cavanaugh Ph.D., Independent Chairman of the Board (Age 77)
- James E. Levine, President, Chief Executive Officer, Director (Age 43)
- Jeffrey G. Black, Chief Financial Officer, Senior Vice President (Age 48)
- Janet S. Roemer, Chief Operating Officer, Executive Vice President - Specialty Enzymes Business Unit (Age 57)
- Alexander A. Fitzpatrick, Senior Vice President, General Counsel, Secretary (Age 47)
- John F. Dee, Independent Director (Age 56)
- Peter R Johnson, Independent Director (Age 61)
- Fernand J. Kaufmann, Independent Director (Age 70)
- Holger A. Liepmann, Independent Director (Age 63)
- Joshua Ruch, Independent Director
How do I buy Verenium stock?
Shares of Verenium can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Verenium's stock price today?
One share of Verenium stock can currently be purchased for approximately $3.99.
How big of a company is Verenium?
Verenium has a market capitalization of $51.01 million.
How can I contact Verenium?
Verenium's mailing address is 3550 John Hopkins Ct, SAN DIEGO, CA 92121-1121, United States. The biotechnology company can be reached via phone at +1-858-4318500.
MarketBeat Community Rating for Verenium (VRNM)MarketBeat's community ratings are surveys of what our community members think about Verenium and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Verenium (NASDAQ:VRNM) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Verenium (NASDAQ:VRNM) Earnings History and Estimates Chart
Verenium (NASDAQ VRNM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2013||Q2 2013||($0.32)||($0.36)||$15.70 million||$15.39 million||View||N/A|
|5/9/2013||Q1 2013||($0.27)||($0.47)||$13.79 million||View||N/A|
|3/27/2013||Q4 2012||($0.29)||($0.28)||$14.32 million||$13.98 million||View||N/A|
|11/8/2012||Q312||($0.41)||$18.42 million||$10.26 million||View||N/A|
Verenium (NASDAQ:VRNM) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Verenium (NASDAQ:VRNM)
No dividend announcements for this company have been tracked by MarketBeat.com
Verenium (NASDAQ VRNM) News Headlines
Verenium (NASDAQ:VRNM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Verenium (NASDAQ:VRNM) Income Statement, Balance Sheet and Cash Flow Statement
Verenium (NASDAQ VRNM) Stock Chart for Sunday, February, 25, 2018